1137949-68-8

Basic information

• Product Name: 3-Bromopyrazolo[1,5-b]pyridazine
• Synonyms: 3-Bromopyrazolo[1,5-b]pyridazine
• CAS NO: 1137949-68-8
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• Mol File: 1137949-68-8.mol

Chemical Properties

• Appearance: /
• Density: 1.891 g/cm³
• PKA: 0.46±0.30(Predicted)
• CAS DataBase Reference: 3-Bromopyrazolo[1,5-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromopyrazolo[1,5-b]pyridazine(1137949-68-8)
• EPA Substance Registry System: 3-Bromopyrazolo[1,5-b]pyridazine(1137949-68-8)

Safety Data

• Hazardous Substances Data: 1137949-68-8(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research and Drug Development:
3-Bromopyrazolo[1,5-b]pyridazine serves as a valuable component in the synthesis and study of other heterocyclic compounds. Its unique structure and properties make it a promising candidate for the development of new pharmaceuticals.
Used in Pharmaceutical Industry:
As a building block, 3-Bromopyrazolo[1,5-b]pyridazine is utilized in the creation of various pharmaceuticals. Its incorporation into drug molecules can potentially enhance their therapeutic effects and contribute to the advancement of medicine.
Used in Agrochemical Industry:
3-Bromopyrazolo[1,5-b]pyridazine also finds application in the development of agrochemicals. Its properties can be harnessed to improve the efficacy of pesticides and other agricultural chemicals, thereby contributing to advancements in agriculture.
Used in Organic Materials Development:
3-Bromopyrazolo[1,5-b]pyridazine's properties make it valuable in the development of organic materials. Its potential applications in this field can lead to the creation of innovative materials with improved performance characteristics, benefiting various industries.

Upstream product

• 53946-83-1 methyl pyrazolo[1,5-b]pyridazine-3-carboxylate 
• 88561-91-5 pyrazolo[1,5-b]pyridazine-3-carboxylic acid 

Downstream Products

• 1146395-28-9 (4-pyrazolo[1,5-b]pyridazin-3-ylphenyl)acetic acid 
• 1202177-91-0 (E)-(3,4-difluorophenyl){5-[(7-pyrazolo[1,5-b]pyridazin-3-yl-2,7-diazaspiro[4.4]non-2-yl)methyl]-2-pyridinyl}methanone O-ethyloxime 

Relevant articles and documents

Decarboxylative Bromination of Heteroarenes: Initial Mechanistic Insights

After an initial report from our laboratory describing metal-free decarboxylative halogenation of various azaheteroarenes, we set out to investigate the possible mechanism by which this chemistry occurs. Evidence from this mechanistic investigation sugges

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5- b]pyridazines for the Treatment of Human African Trypanosomiasis

From a high-throughput screen of 42 44 known human kinases inhibitors, a pyrazolo[1,5-b]pyridazine scaffold was identified to begin optimization for the treatment of human African trypanosomiasis. Previously reported data for analogous compounds against h

DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR

[Problems] To provide an antagonist of a melanin-concentrating hormone receptor, which is useful as a medicine for a central nervous system disease, a cardiovascular disease or a metabolic disease. [Means for Solving Problems] The antagonist comprises, as an active ingredient, a compound represented by the formula (I) wherein R1a and R1b independently represent a hydrogen atom or a C1-6 alkyl group; R2a, R2b, R3a and R3b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Y represents H or —OH; Z represents —OR8, or the like; R8 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, or the like; R9a and R9b independently represent a hydrogen atom, a C1-6 alkyl group, or the like; Ar1 represents an aromatic carbon ring group, or an aromatic heteroring group; Ar2 represents a group produced by removing two hydrogen atoms from an aromatic carbon ring, or the like; and the ring group A represents an unsaturated heteroring group.